In Vitro Propagated Dendritic Cells from Patients with Human-Papilloma Virus-Associated Preneoplastic Lesions of the Uterine Cervix: Use of Flt3 Ligand by Hubert, Pascale et al.
ORIGINAL ARTICLE
Pascale Hubert á Roland Greimers á
Elizabeth Franzen-Detrooz á Jean Doyen á
Pierre Delanaye á Jacques Boniver á
Philippe Delvenne
In vitro propagated dendritic cells from patients
with human-papilloma virus-associated preneoplastic lesions
of the uterine cervix: use of Flt3 ligand
Received: 8 January 1998 /Accepted: 30 April 1998
Abstract Dendritic cells (DC) are the most ecient
antigen presenting cells. The clinical use of DC as vec-
tors for antitumor and anti-infectious disease immuno-
therapy has been limited by their low level and
accessibility in normal tissue. Substantial numbers of
DC can be generated from peripheral blood cultured in
the presence of interleukin-4 (IL-4) and granulocyte/
macrophage-colony-stimulating factor (GM-CSF). We
showed in this study that substantial numbers of DC can
be obtained from the peripheral blood of patients with
(pre)neoplastic lesions of the uterine cervix. The proce-
dure required relatively small blood samples (10 ml) and
the presence of 100 U/ml IL-4 and 800 U/ml GM-CSF
in the culture medium. There was no significant dier-
ence in the morphology, yield, phenotype and function
of generated DC between patients with cervical (pre)-
neoplastic lesions and healthy individuals. When the
hematopoietic factor Flt3 ligand (Flt3L, 40 ng/ml) was
added, there was an average increase in the DC popu-
lation of 26% compared to cultures with GM-CSF
and IL-4 alone. Approximately 1.2 ´ 106 cells with the
characteristics of dendritic cells could be obtained when
Flt3L was included in the medium. The addition of
Flt3L did not modify the phenotypic profile of DC
(HLA-DR+, CD1a+, CD4+, CD54+, CD80+, CD86+,
CD40+, CD3) and CD14)). In addition, Flt3L gener-
ated functional DC capable of stimulating the prolifer-
ation of alloreactive T cells. These results suggest that
Flt3L, in association with GM-CSF and IL-4, provides
an advantageous tool for the large-scale generation of
DC and that an immunotherapy based on the use of DC
generated in vitro is possible in patients with (pre)neo-
plastic lesions of the uterine cervix.
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Introduction
Accumulation of immunological, molecular and clinical
evidence has implicated human papillomavirus (HPV)
infection as an essential factor in the development of
invasive cervical cancer and its precursor lesions [22, 31].
Squamous intraepithelial lesions (SIL) refer to a group
of premalignant changes in the epithelium of the uterine
cervix that precede the onset of invasive cancer.
The general or local immune state might be expected
to have a key role in host defense against HPV infection
and the possible development of cervical carcinoma. The
nature of an eective immune response to HPV infec-
tions is not well understood, although cell-mediated
immunity is thought to be more important than humoral
immunity [50]. Several studies have described a localized
immune dysfunction accompanying cervical HPV in-
fections and associated cervical lesions. Specifically, al-
terations in the number and cytokine profiles of T helper
lymphocytes have been reported [2, 5, 49]. On the other
hand, alterations in the density, distribution and mor-
phology of Langerhans cells have been shown in both
papillomavirus-infected and (pre)neoplastic cervical ep-
ithelium [30]. Several explanations have been proposed
to explain the changes of Langerhans cells locally in SIL
[16, 21, 29]. These lesions develop in the transformation
zone of the cervix, where there is a low density of Lan-
gerhans cells, even in the absence of HPV infection [1, 2,
8]. Other authors have suggested that these changes
might be due to the cytopathic eect of the virus [38].
Alterations of membrane molecules of infected keratin-
ocytes (loss of E-cadherin) might contribute to the re-
duction of Langerhans cells or to their functional
inability [48]. HPV infection of the keratinocytes has
been shown to alter the production of immunoregula-
tory cytokines that are likely to have a stimulatory eect
on Langerhans cells (tumor necrosis factor a, TNFa;
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granulocyte/macrophage-colony-stimulating factor, GM-
CSF) [27]. Another possibility is that the immunosup-
pressive cytokine interleukin-10 (IL-10), which is
expressed in SIL, plays a role in the depletion or inhi-
bition of Langerhans cells [13]. Langerhans cells belong
to the family of dendritic cells (DC), which are the most
important professional antigen-presenting cells (APC) in
the immune system. Because host professional APC are
among the most important elements in the induction of
specific antitumor immune responses, quantitative or
qualitative alterations of these cells could be partly re-
sponsible for the immunotolerance of HPV-associated
cervical (pre)neoplastic lesions.
Although DC are present in small numbers, they act
as sentinels of the immune system because they are
widely distributed in the body [36]. DC are critically
involved in the initiation of primary immune responses,
in vivo graft rejection and development of T-cell-
dependent antibodies [4, 46]. Unlike other APC
(monocytes, macrophages), DC may be crucial because
of their potential to recruit resting T cells to initiate an
immune response [20]. They are very specialised in this
function, as reflected by their constitutive expression of
high levels of major histocompatibility complex class II
molecules, adhesion molecules and expression of CD80
(B7.1) and CD86 (B7.2) on their surface [6, 10].
By virtue of their developed antigen-presenting ca-
pacity, DC are ideal targets to manipulate the immune
system. The use of DC as cellular vectors for antitumor
and anti-infectious disease vaccines or as inducers of
transplantation tolerance is a promising immunotherapy
strategy [26, 51]. However, the clinical feasibility of
using DC as immunotherapy vectors has been hampered
by their scattered location and very low frequency [7].
In recent years, several laboratories have devised
dierent methods to amplify the number of DC by
culturing DC precursors from dierent origins. DC can
be generated from CD34+ hematopoietic progenitor
cells isolated from bone marrow of healthy donors [34,
43] or from peripheral blood of cancer patients under-
going autologous stem-cell transplantation [3]. Cord
blood has been reported to be another source of CD34+
progenitor cells [40]. Both the proliferation and matu-
ration of DC are enhanced by the cooperation of GM-
CSF and TNFa [35]. However, the applicability of these
approaches has been somewhat limited by the low levels
of CD34+ cells and by the relatively tedious techniques
required. Recently, another source of DC progenitors
(monocytic precursors) has been discovered in adult
blood [37]. Indeed, the dierentiation of DC involves at
least two pathways. DC can be generated from an early
bone marrow precursor (CD34+) or from cells of the
monocytic lineage (CD14+) [32]. The monocytic pre-
cursors are induced to proliferate and to dierentiate in
the presence of GM-CSF and IL-4. IL-4 acts by sup-
pressing macrophage development and by favoring dif-
ferentiation of DC from monocytic precursors [19].
Whatever the approach used to obtain DC (from
CD34+ or monocytic precursors), their yield depends
mainly on the initial number of precursor cells. This
suggests that the ex vivo generation of large numbers of
DC may benefit from the addition of hematopoietic
growth factors. Flt3L is a recently identified hemato-
poietic growth factor [24]. It has been shown to stimu-
late the proliferation of hematopoietic stem and
progenitor cells [23, 28] and to induce the proliferation
and dierentiation of monocytes [11].
The purposes of this study were to examine the eect
of Flt3L on the maturation of DC from peripheral blood
and to determine whether the generation of DC diers
between healthy donors and patients with cervical SIL.
We have shown that Flt3L is very ecient in increasing
the generation of DC from human peripheral blood
mononuclear cells (PBMC), without altering their phe-
notype or allostimulatory capacities. No dierence was
observed between patients with SIL and healthy women.
These results might help to improve our understanding
of the role of DC in HPV infections and malignant
diseases and help us to evaluate the potential use of DC
in HPV-associated cancer immunotherapy.
Materials and methods
Culture medium
The medium used in this study was RPMI-1640 supplemented with
10% heat-inactivated fetal calf serum (FCS), 1% non-essential
amino acids, 1% sodium pyruvate, 50 lM 2-mercaptoethanol,
30 U/ml penicillin, and 30 lg=ml streptomycin (all obtained from
Gibco BRL, Life Technologies). This medium is reported to as
complete medium.
Recombinant human cytokines and growth factors
GM-CSF (11.1 ´ 106 U/mg) was kindly provided by Dr. A. Gos-
sens (Schering-Plough, Brussels). IL-4 (5 ´ 106 U/mg) and Flt3L
(1:1 106 U=mgÿ 20 lg=ml) were purchased from Genzyme Di-
agnostics (Cambridge, Mass.).
Study group
Fifteen patients with histologically confirmed SIL of the cervix
were selected for this study. Biopsies were diagnosed as low-grade
SIL in five patients and as high-grade SIL in ten patients. The mean
age of the group was 33 years. Six age-matched healthy volunteers
were used as controls.
Dendritic cell cultures
Peripheral blood was collected on EDTA from the patients before
laser conisation. In some experiments, leukocyte-enriched buy-
coats were used as a source of mononuclear cells.
PBMC were isolated by Ficoll-Hypaque density-gradient cen-
trifugation. After washings at low centrifugation speed to remove
the maximum number of platelets, PBMC were plated in six-well
dishes (Nunclon D Multidishes, Nunc, Denmark) at a density of
10 ´ 106 cells/well in 3 ml complete medium without FCS. After
18 h at 37 °C, non-adherent cells were discarded by two gentle
washes with 1.5 ml complete medium. The adherent cells were
cultured with 800 U/ml GM-CSF and dierent concentrations of
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IL-4 (see results) in 3 ml complete medium/well. These cultures
were supplemented or not with dierent concentrations of Flt3L
(see results). IL-4 was added every 2 days and cultures were fed
every 3 or 4 days with fresh medium containing the appropriate
cytokines. Cells were harvested at dierent times points (day 7, 14
and 21) for phenotypic, morphological and functional analysis.
Harvesting was performed by adding 1.5 ml EDTA 1 mM in
phosphate-buered saline without calcium, for 20 min at room
temperature.
Flow-cytometric cell surface marker analysis
Samples containing 4–5 ´ 105 cells were incubated for 20 min at
4 °C in Hank’s buer (Life Technologies) with specific mAb (listed
in Table 1). Cells were stained either directly with fluorescein-
isothiocyanate(FITC)- or phycoerythrin(PE)-conjugated mono-
clonal antibodies (1/5 dilution), or indirectly with streptavidin-PE
(2 ll/staining, Boehringer Mannheim) or with irrelevant control
isotype-matched mAb (Becton-Dickinson). After washing, cells
were resuspended in Hank’s buer and analyzed. Two- or three-
fluorescent-color staining was performed. Propidium iodide (1 lg/
ml) was used to exclude dead cells. Cells were analyzed for fluo-
rescence intensity on a FACStarPlus flow cytometer (Becton Dic-
kinson). Forward light scattering, orthogonal light scattering and
three fluorescence signals were determined for each cell and at least
20 000 events were accumulated for each measurement.
Cytochemical staining
Cytospins of DC cultures were prepared by spinning (200 rpm)
(0.5–1) ´ 105 cells onto silanized slides and fixed in cold acetone for
3 min. Giemsa staining was performed using standard procedures.
Mixed lymphocyte reaction assay
Stimulator populations consisted of cells grown in GM-CSF + IL-
4 (100 U/ml) or GM-CSF + IL-4 + Flt3L for 7 days. After cen-
trifugation for 10 min at 200 g, the cells were adjusted to equal
concentration in RPMI-1640 medium containing 5% human
pooled AB serum without exogenous cytokines and irradiated with
30 Gy. Varying numbers of stimulator cells (500–50 000 cells/well)
were then added to round-bottomed 96-well plates (Nunclon)
containing 1 ´ 105 allogeneic PBMC/well. The tests were per-
formed in quintuplate. A proliferative response was measured
after 6 days of culture by adding 1 lCi [3H]thymidine to each
well. Cells were harvested 18 h later by an automated sample
harvester (Packard, Canberra, Tilburg, The Netherlands) and
counted in a liquid scintillation counter (Top Count, Packard,
Canberra). Thymidine uptake in irradiated stimulator cells was
below 640 cpm and in responder cells cultures alone it was below
240 cpm.
Statistical analysis
In experiments concerning the eect of Flt3L on HPV patients
compared with healthy donors, the Mann-Whitney test for paired
samples was used for statistical evaluation. In other experiments,
the analysis of variance test for paired samples was used.
Results
Assessment of the optimal culture conditions
for the generation of DC from adherent PBMC
Before working on the generation of DC from the pe-
ripheral blood of patients with SIL, we optimised the IL-
4 concentration in the cultures by using buy-coat
samples from normal donors as sources of PBMC.
Following the 18-h adherence to plastic at 37 °C, we
observed an adherent fraction made up of monocytes
(47  10%) and lymphocytes (41.9  22%). This ad-
herent fraction was cultured in RPMI-1640/10% FCS
supplemented with 800 U/ml GM-CSF, as recom-
mended by previous studies [29, 33], and various
concentrations of IL-4 (0–1000 U/ml). Fluorescence-
activated cell sorting (FACS) analysis, with an anti-
CD1a monoclonal antibody, was performed to deter-
mine the yield of DC obtained after 7, 14 and 21 days of
culture. Figure 1A shows the results expressed as the
percentage increase of CD1a+ cells in the presence of
various doses of IL-4 compared with cultures containing
GM-CSF alone. The maximum yield of CD1a+ cell was
observed at day 7 of culture with 100 U/ml IL-4
(P < 0.001). With these culture conditions, 63  18%
of the cells showed a phenotype of dierentiated DC
(CD1a+/CD14)). The range of increase, compared with
CD1a+ cells obtained at day 7 with 1000 U/ml of IL-4,
was 30%–50%. After long-term cultures (14 and
21 days), the number of total nucleated cells decreased as
well as the yield of DC. This observation was docu-
mented in four independent cell cultures.
We also tested the eect of graded doses of Flt3L
(0–80 ng/ml) on PBMC from buy-coats of healthy
donors. Flt3L, at a concentration of 40 ng/ml, in asso-
ciation with GM-CSF and IL-4, induced the maximal
expansion of CD1a+ cells in all donors examined. We
showed that these conditions were responsible for a
mean increase of 50% in the number of DC (P < 0.001)
(Fig. 1B).
For subsequent experiments, we therefore decided
to use 40 ng/ml Flt3L, 100 U/ml IL-4 and 800 U/ml
GM-CSF to generate DC.
Morphological and phenotypical analysis
of CD1a+ cells cultures in the presence of Flt3L
The monocytic adherent fraction of 10 ´ 106 mononu-
clear cells from peripheral blood of patients with SIL or
from healthy individuals was cultured in medium con-
taining GM-CSF (800 U/ml) and IL-4 (100 U/ml) sup-
Table 1 List of antibodies. Sources: Becton Dickinson (Erembo-
degem, Belgium). (BD); Ortho Diagnostics (Raritan, N. J.) (Ortho);
Dako (Glostrup, Denmark); Pharmingen (San Diego, Calif.).
FITC fluorescein isothiocyanate, PE phycoerythrin
Marker mAb Conjugated Source
CD1a OKT6 FITC Ortho
CD3 Leu-4 PE BD
CD4 Leu-3a PE Dako
CD14 Leu-M3 PE BD
CD54 ICAM-1 PE Pharmingen
CD80 BB1/B7.1 PE BD
CD86 B70/B7.2 Biotin Pharmingen
HLA-DR HLA-DR PE BD
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plemented or not with Flt3L at a concentration of 40 ng/
ml, as previously determined. Phase-contrast microsco-
py of these cultures, with or without Flt3L, revealed the
presence of cell aggregates containing a few cells after
2–3 days. These aggregates enlarged over the next few
days (day 4–5) indicating proliferative activity. Many of
the cells displayed the typical cytoplasmic processes
(usually termed veils) peculiar to DC (data not shown).
Over the next few days, these veiled DC were slowly
released. There was no morphological dierence be-
tween cells cultured with GM-CSF + IL-4 alone and
those cultured in medium supplemented with Flt3L
(Fig. 2). These observations were similar for cells from
patients with SIL and healthy donors.
We also compared the phenotype of DC generated
with and without Flt3L by FACS analysis. DC could be
distinguished from contaminating lymphocytes by their
size and granularity. As shown in Fig. 3A, gated cells
containing DC presented significantly increased for-
ward-scatter and side-scatter values as compared with
lymphocytes. Therefore, we used these parameters to
gate the DC. The gated cell population was similar for
cultures unsupplemented or supplemented with Flt3L.
Between 20% and 75% of the cells cultured without
Flt3L were in this gate compared to 30%–80% for cells
generated with Flt3L. Thus, the DC dierentiation
pathway (with and without Flt3L) was associated with
the same changes in size and granularity, leading to cells
that were considerably larger and more dense than
granulocytes and monocytes. Figure 3B demonstrates
that the cells generated with or without Flt3L display the
typical surface phenotype of dendritic cells [32]: (1) ex-
pression of the Langerhans/dendritic cell molecule
CD1a, (2) co-expression of CD4, and (3) absence of the
macrophage and T cell markers CD14 and CD3. How-
ever, small numbers of CD3+ and CD20+ (not shown)
cells were detected by FACS analysis in the gated cell
population and were probably related to the formation
of cell ‘‘rosettes’’ between DC and either T cells or B
cells. Other typical features included (4) increased ex-
pression of class II MHC (HLA-DR) molecules, (5)
high-level expression of the adhesion molecules ICAM-1
(CD54) and CD40, and (6) expression of the co-stimu-
latory molecules B7.1 (CD80) and B7.2 (CD86). No
dierences were observed in the level of expression of all
these markers in cultures with and without Flt3L. Pa-
tients with SIL did not dier significantly from control
individuals.
Eects of Flt3L on the yield of DC in patients
with cervical SIL and healthy donors
The eect of Flt3L on CD1a+ cell generation was ex-
amined using peripheral blood from 15 patients with
HPV-associated SIL and 6 healthy donors. At day 7,
cells cultured in GM-CSF + IL-4, with or without
Flt3L, were counted and the number of CD1a+ cells was
determined by FACS analysis. Addition of Flt3L to the
culture medium did not result in a significant increase in
the total number of cells either in patients with SIL or in
healthy donors (data not shown). In contrast, the ad-
dition of Flt3L induced an important and significant
expansion of CD1a+ cells either in patients with SIL
(P < 0.0001) or in control individuals (P  0.0312).
The results are expressed, in Fig. 4, as the percentage
increase in CD1a+ cells, compared with cells cultured in
normal medium (GM-CSF + IL-4 alone), for each
PBMC donor.
Interestingly, the proportion of DC obtained in cul-
tures without Flt3L from patients with SIL was the same
as that from control individuals. When Flt3L was add-
ed, this proportion increased, but to the same extent in
both patients and healthy individuals (data not shown).
The eect of Flt3L on the yield of CD1a+ cells varied
among donors. The individual increments observed with
Flt3L varied between 18% and 53% with a mean in-
Fig. 1A, B Assessement of the optimal culture conditions for the
generation of dendritic cells (DC) from adherent peripheral blood
mononuclear cells (PBMC). A Average percentage CD1a+ cell
increase in the presence of 100 U/ml interleukin-4 (IL-4). Means
(bars SE) of four experiments are shown. B Eect of dierent
concentrations of Flt3L on the number of CD1a+ cells obtained
per well. Results are presented the percentage increase compared
with cultures containing normal medium [granulocyte/macro-
phage-colony-stimulating factor (GM-CSF) + IL-4]. Means (bars
SE) of three experiments are shown
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crease of 26% for the patients and 34% for the healthy
donors. This dierence was not significant.
When Flt3L was added to the culture,
(1.14  0.26) ´ 106 (n  7) CD1a+ cells were obtained
after 7 days from blood samples having a volume as low
as 10 ml. Similar results were obtained for both patients
and healthy individuals.
Functionality of DC generated with
and without Flt3L. Allostimulatory capacity
Cell populations from cultures with and without Flt3L
for one healthy donor and two patients with SIL were
compared for their capacity to provide accessory signals
for an ecient proliferation of responder cells in an
allogeneic test.
As shown in Fig. 5, the capacity to produce a potent
mixed lymphocyte reaction was retained even at stimu-
lator:responder ratios as low as 1000:100 000, which is
consistent with a DC-mediated T cell response [47]. DC
generated from precursors in the peripheral blood
of patients and DC obtained from healthy donors did
not dier significantly in their ability to stimulate an
allogeneic response.
The stimulatory capacity of the cell population gen-
erated with GM-CSF + IL-4 + Flt3L was generally
higher than that of the population induced with GM-
CSF + IL-4. These results support the idea that there
was a higher proportion of stimulatory cells (i.e. DC
cells) in the populations generated with Flt3L.
PBMC from the same donors were used as controls
and were much less eective in all assays. Independently
of the cytokines used to generate DC, mixed lymphocyte
reactivity correlated with the percentage of CD1a+/
CD14) cells present among stimulating cells (data not
shown).
Discussion
This study was designed to assess the optimal modalities
for the large-scale procurement of functional DC start-
ing from a relative small quantity (10 ml) of peripheral
blood from patients with preneoplastic lesions of the
uterine cervix (SIL) and to determine whether the gen-
eration of DC diers between healthy women and pa-
tients with SIL, since tumor-derived factors have been
shown to aect the ability of precursors to dierentiate
into DC [12]. Moreover, previous studies have reported
a depletion and qualitative alterations of Langerhans
cells in SIL compared to a normal squamous mucosa
during the HPV-associated cervical carcinogenesis [1,
45]. This finding might be due to an altered generation of
DC or to a lack of maturation/migration of DC in re-
lation to a decreased production of chemotactic factors
by epithelial cells in the presence of HPV [14]. Because of
the central role of DC in the generation of an eective
cellular immune response, a defect in these cells might
make the development of a specific CTL response almost
impossible in neoplastic cervical epithelium infected with
HPV. These observations highlight the need for methods
generating a large-scale production of DC in vitro for a
better understanding of their role in HPV-associated
(pre)neoplastic lesions. The development of methods
generating a large number of functionally active DC was
prompted by studies suggesting that administration of
tumor-antigen-pulsed DC to cancer patients might help
to counteract disturbance of immune functions [15]. In
the field of HPV-associated pathology, some experi-
ments have shown that a protective and therapeutic
Fig. 2A, B Morphology of DC
cultured in medium containing
GM-CSF and IL-4 and supple-
mented with Flt3L (A) or unsup-
plemented (B). The cytospins were
colored with May-Grumwald-Gi-
emsa stain. Cells display a dendritic
morphology with delicate mem-
brane projections
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antitumor immunity may be generated against HPV-
transformed cells in animals by using vaccination pro-
tocols with viral-peptide-pulsed autologous DC [26, 52].
In humans, this approach was shown to be eective for
inducing peptide-specific CTL that recognise processed
E6 and E7 peptides in vitro [9]. An ecient expansion of
autologous DC might therefore be clinically useful.
Several investigators have shown that DC may be gen-
erated in liquid suspension cultures from blood mono-
cytic precursors by using a combination of GM-CSF
and IL-4 [17, 35, 37]. However, this technique is limited
by the low frequency of monocytic precursors. The he-
matopoietic activity of some stimulatory factors such as
Flt3L [11, 23, 24] might help to improve the production
of DC from PBMC. Currently, hematopoietic growth
factors have been tested for their eect on bone marrow
progenitor cells [25, 41, 43] and not on monocytic pre-
cursors. By using a combination of IL-4 (100 U/ml),
GM-CSF (800 U/ml) and Flt3L (40 ng/ml), we were
able to produce, after 7 days of culture, between
1.14 ´ 106 and 1.4 ´ 106 CD1a+ cells from the adherent
fraction of 10 ´ 106 PBMC (present in 8–10 ml periph-
eral blood of healthy individuals and patients with
cervical SIL). The generation of DC from monocytic
precursors was maximal in the presence of 100 U/ml IL-
4. Previous studies used higher concentrations of IL-4
(500–1000 U/ml IL-4) and no Flt3L [33, 37, 39] and
reported a yield of DC (3 ´ 106 CD1a+ cells for 40 ml
b
Fig. 3A, B Cell-surface membrane phenotype of DC generated on
day 7 with and without Flt3L as detected by dual-color direct
immunofluorescence and flow cytometry. A DC can be distin-
guished in the two culture conditions by their high forward- and
side-scatter properties. B DC display the typical phenotype of
dendritic cells in the two culture conditions. Patterns of isotype-
matched control antibodies are included in each histogram (dotted
lines). Fluorescence intensity (x axis) is plotted against the number
of events (y axis). Each result is representative of seven experiments
Fig. 4 Individual percentage CD1a+ cell increases in the presence
of Flt3L (40 ng/ml) compared with number of CD1a+ cells
generated in medium with GM-CSF + IL-4 alone. Results are
shown for patients with SIL and healthy donors
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blood) that is lower than that obtained in this study. We
found that higher IL-4 concentrations than 100 U/ml
were associated with a decrease in the number of total
mononuclear cells and consequently in the number of
CDla+ cells. Moreover, low concentrations of IL-4 are
closer to the equilibrium constant of that cytokine in vivo
(50–200 U/ml). These low concentrations of IL-4 also
induce not only a dierentiation of monocytes to DC
but 36% of these DC show the presence of intracyto-
plasmic granules that are reminiscent of Langerhans cell
Birbeck granules (Dr. Grassi, personal communication).
Therefore, the use of 100 U/ml IL-4 may generate cells
morphologically closer to Langerhans cells, the density
of which has been shown to be low in HPV-transformed
(pre)neoplastic cervical epithelium. The combination of
Flt3L + GM-CSF + IL-4 was associated with a mean
increase of 26% in DC production, compared with a
culture without Flt3L. The precise mechanism of action
by which Flt3L, in association with GM-CSF and IL-4,
stimulates the production of DC remains unclear and
requires further studies. One possibility is that Flt3L acts
on CD34+ cells present in the adherent fraction of
PBMC. Indeed, recent studies indicate that Flt3 receptor
is expressed on purified CD34+ cells [44] and absent on
CD34) cells [11]. Moreover, a variable number of
CD34+ cells in each donor might explain the variable
increase in CD1a+ cells with Flt3L. However, it is very
dicult to determine whether the percentage of CD34+
cells in the starting population accounts for the inter-
donor variation because the frequency of these progen-
itors is too low to be detected with accuracy by FACS
analysis. Another possibility is that Flt3L synergizes
with GM-CSF to stimulate the proliferation and dier-
entiation of monocytic cells [42]. Since the combination
GM-CSF + IL-4 acts on the monocytic precursor
population to induce DC dierentiation [37], Flt3L
might increase the yield of DC by stimulating the pro-
liferation of monocytes and so boosting the level of
precursor cells (CD14+).
We did not detect any significant dierence in the
phenotypical profile of DC generated with or without
Flt3L. The generated cells were positive for the classical
DC markers (CD1a, CD4, class II MHC, CD80, CD86,
CD54, CD40). These molecules were highly expressed
without major changes in antigen density. Further
functional analysis revealed that the ability to stimulate
allogeneic responder cells (PBMC) was retained in GM-
CSF + IL-4 + Flt3L cultures. We also compared the
phenotype and the functionality of DC generated from
the peripheral blood of healthy donors and from pa-
tients with SIL. There was no significant dierence in the
phenotype and functional activity of DC between con-
trol individuals and patients with SIL. The increased DC
yield induced by Flt3L was also observed in both pop-
ulations. The systemic alterations of the immune system
observed in patients with SIL [18] do not seem, there-
fore, to influence the presence of DC precursors in the
blood, and the decrease of Langerhans cells observed in
SIL is probably related to local mechanisms (such as
lack of maturation in situ or lack of chemotactic factors
produced by HPV-infected keratinocytes) rather than a
systemic mechanism aecting DC precursors.
In summary, we have described a simple method al-
lowing the generation of a large number of functional
DC from a relatively small amount of blood in both
healthy donors and patients with SIL. The results of this
study suggest that Flt3L is a promising growth factor for
the in vitro generation of large number of DC, which
might help to improve our understanding of the cervical
carcinogenesis and be used in clinical immunothera-
peutic anti cancer protocols.
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